Approval · Notice of Compliance 334 · 2002
NEUROLITE: Notice of Compliance 334
Issued February 15, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 334
- Date
- February 15, 2002
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Radiopharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Manufacturer name change
- Therapeutic class
- Radiodiagnostic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NEUROLITE | Not yet assigned | — |
Medicinal ingredients
- BICISATE DIHYDROCHLORIDE 0.9 MG per VIAL